Groupe Oncologie Radiotherapie Tete et Cou
Quick facts
Marketed products
- 5-Fluorouracile · Oncology
5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death. - Ethyol · Other
Phase 3 pipeline
- Carboplatin, 5FU concomitant · Oncology
Carboplatin and 5-fluorouracil (5FU) work together as chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells. - concomitant cisplatin · Oncology
Cisplatin works by interfering with DNA replication, causing cell death in rapidly dividing cancer cells. - Ligufalimab · Other
Phase 2 pipeline
- Carbo, 5FU, Cetuximab · Oncology
Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells. - cetuximab IV
- Split Cisplatin
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Groupe Oncologie Radiotherapie Tete et Cou portfolio CI brief
- Groupe Oncologie Radiotherapie Tete et Cou pipeline updates RSS
Frequently asked questions about Groupe Oncologie Radiotherapie Tete et Cou
What are Groupe Oncologie Radiotherapie Tete et Cou's marketed drugs?
Top marketed products include 5-Fluorouracile, Ethyol.
What is Groupe Oncologie Radiotherapie Tete et Cou's pipeline?
Groupe Oncologie Radiotherapie Tete et Cou has 3 drugs in Phase 3, 3 in Phase 2, 1 in Phase 1. Late-stage candidates include Carboplatin, 5FU concomitant, concomitant cisplatin, Ligufalimab.
Related
- 5-Fluorouracile · Oncology
- Ethyol · Other
- Sector hub: All tracked pharma companies